Jefferies Group's KYTX Position Overview
Jefferies Group (via Jefferies Financial Group Inc.) currently holds 23,920 shares of Kyverna Therapeutics, Inc. (KYTX) worth $206,430, representing 0.00% of the portfolio. First purchased in 2025-Q3, this short-term holding has been held for 3 quarters.
Based on 13F filings, Jefferies Group has maintained this position in KYTX for several quarters, showing initial confidence in the investment. Largest addition occurred in Q4 2025, adding 15,701 shares. Largest reduction occurred in Q1 2026, reducing 8,081 shares.
Analysis based on 13F filings available since 2013 Q2
Jefferies Group's Kyverna Therapeutics (KYTX) Holding Value Over Time
Track share changes against reported price movement
Quarterly Kyverna Therapeutics (KYTX) Trades by Jefferies Group
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q1 2026 | -8,081 | Reduce 25.25% | 23,920 | $8.63 |
| Q4 2025 | +15,701 | Add 96.33% | 32,001 | $9.40 |
| Q3 2025 | +16,300 | New Buy | 16,300 | $6.00 |
Jefferies Group's Kyverna Therapeutics Investment FAQs
Jefferies Group first purchased Kyverna Therapeutics, Inc. (KYTX) in Q3 2025, acquiring 16,300 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Jefferies Group has held Kyverna Therapeutics, Inc. (KYTX) for 3 quarters since Q3 2025.
Jefferies Group's largest addition to Kyverna Therapeutics, Inc. (KYTX) was in Q3 2025, adding 16,300 shares worth $97,800.
According to the latest 13F filing for Q1 2026, Jefferies Group's firm, Jefferies Financial Group Inc., owns 23,920 shares of Kyverna Therapeutics, Inc. (KYTX), valued at approximately $206,430.
As of the Q1 2026 filing, Kyverna Therapeutics, Inc. (KYTX) represents approximately 0.00% of Jefferies Group's publicly disclosed stock portfolio, making it one of their key holdings.
Jefferies Group's peak holding in Kyverna Therapeutics, Inc. (KYTX) was 32,001 shares, as reported at the end of Q4 2025.